System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Andreas Schneeweiss, MD is an expert in Oncology at National Center for Tumor Diseases (Germany). As of October 2026, ScienceLeadR ranks Andreas Schneeweiss in the top 1% of experts worldwide for Breast Diseases and Breast Neoplasms. Andreas Schneeweiss has authored 1,275 publications, the most recent in 2026, and is an investigator in 68 clinical trials, 17 of them ongoing. SLR score: 4,711 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Andreas Schneeweiss, MD National Center for Tumor Diseases Germany
4 711 ScienceLeadR Reputation 4711

Unlock

Register Login
Network Map

Oncology

Subspecialties: Surgery - Dermatology - Gynecology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2001 - 2026
Source: PubMed

German Cancer Research Center

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1275

Citations

Citations: 62 777 1st author: 105 Last author: 125 Unique author: 12

Main journals

Cancer Res 162
J Clin Oncol 112
Geburtshilfe Frauenheilkd 111
Ann Oncol 104
Senologie - Zeitschrift für Mammadiagnostik und -therapie 80

Best Journals

Ann Oncol 52
J Clin Oncol 30
N Engl J Med 17

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Real-Time Electronic Patient-Reported Outcome Monitoring With Digital Triage and Care-Team Integration in Early Breast Cancer: ENABLE Randomized Controlled Trial.
PMID 42954133 — depression, quality of life, breast neoplasms, pain, triage, neoplasms, fatigue, breast, therapeutics		J Med Internet Res20260
Neuroendocrine Differentiation Mediates Escape from HER2-Targeted Therapy in Breast Cancer.
PMID 42949420 — cells, breast neoplasms, neoplasms, breast, therapeutics		Cancer Discov Top journal20260
CPS + EG and Neo-Bioscore predict individual outcomes but not trial results after neoadjuvant therapy for early breast cancer.
PMID 42945961 — disease-free survival, breast neoplasms, neoplasms, breast, neoadjuvant therapy, therapeutics		Cancer Cell Top journal20260
AGO Breast Panel Recommendations for the use of treatment-relevant biomarkers in early and advanced breast cancer-2026 Update.
PMID 42497646 — breast neoplasms, neoplasms, biomarkers, breast, therapeutics		Breast20262
Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab.
PMID 42727049 — triple negative breast neoplasms, blood, breast neoplasms, neoplasms, drug therapy, breast, precision medicine, therapeutics, chemotherapy		JCO Precis Oncol20260

Clinical Studies 68

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4 Study Chair: 2

By phase:

Phase 3 38
N/A 11
Phase 2 10
Phase 1 3
Phase 1/Phase 2 3
Phase 4 2
Phase 2/Phase 3 1

By status:

Completed 39
Active not recruiting 16
Recruiting 8
Unknown 3
No longer available 1
Terminated 1

By type:

Interventional 61
Observational 6
Expanded Access 1

By Monocentric/Multicentric:

monocentric 18
multicentric2to4 2
multicentric5to9 2
multicentricup10 46

Main Topics

Ongoing Clinical Trials

17 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Evaluate the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician s Choice of Endocrine Therapy Plus Everolimus in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer
2023-506821-12-00 — estrogens, safety, breast neoplasms, receptors, estrogen, neoplasms, everolimus, breast, therapeutics		Phase 3Active not recruiting2023
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4 6 inhibitor) in Participants with ER HER2 Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
2022-502980-39-00 — fulvestrant, estrogens, safety, breast neoplasms, receptors, estrogen, neoplasms, breast, therapeutics		Phase 3Active not recruiting2024
A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versus subcutaneous pertuzumab and trastuzumab alone in people with previously untreated locally advanced or metastatic breast cancer with HER2 and oestrogen receptor positivity
2022-500014-26-00 — estrogens, safety, breast neoplasms, receptors, estrogen, neoplasms, maintenance, breast, therapeutics, trastuzumab		Phase 3Active not recruiting2022
A Study of Disitamab Vedotin with Other Anticancer Drugs in Solid Tumors
2023-507555-29-00 — breast neoplasms, pharmaceutical preparations, esophagogastric junction, neoplasms, adenocarcinoma, breast, therapeutics, stomach neoplasms		Phase 1/Phase 2Active not recruiting2024
An open label phase I II multicenter clinical trial of NECVAX NEO1 as add on to first line neoadjuvant anti PD 1 monoclonal antibody therapy in patients with triple negative breast cancer
2024-512520-11-00 — triple negative breast neoplasms, breast neoplasms, neoplasms, breast, antibodies, monoclonal, therapeutics		Phase 1/Phase 2Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS